Tag: Stem Cells
FDA Approves Darzalex Faspro for Treating Multiple Myeloma
The quadruplet regimen was approved for stem cell transplant-eligible patients
Socioeconomic Status of Stem Cell Donor Affects Recipient Health Outcomes
Recipients receiving cells from donors in lowest quartile of SES experienced reduction in overall survival, increase in treatment-linked mortality
Successful Pregnancy Possible for Stem Cell Transplant Recipients
Annual first birth rate 0.45 percent, which was more than six times lower than in general population
Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia
PTCy GVHD prophylaxis after allogeneic stem cell transplant yields comparable relapse incidence, lower GVHD
Mesenchymal Stem Cell-Neural Progenitors Beneficial for MS
More improvement in timed 25-foot walk, six-minute walk test seen among those requiring assistance for ambulation
Positive Psychology Intervention Aids Allogeneic Stem Cell Transplant Survivors
Greater improvements reported in gratitude, anxiety, physical function at nine weeks; more improvements seen at 18 weeks
Hematopoietic Cell Transplantation Use Has Increased for All Racial Groups
Rates of increase significantly higher for Hispanics and non-Hispanic African Americans for autologous, allogeneic HCT
Improvements Seen in Post-Allo-HCT Outcomes for Seniors With Leukemia
Reduction in relapse incidence observed over time, as well as improvement in leukemia-free survival, overall survival
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
Three-year overall and disease-free survival, three-year cumulative incidence of relapse similar between the groups
Risk for Vitiligo Increased for Transplant Recipients
Increased risk seen for those receiving allogeneic grafts and autologous grafts, as well as those with and without comorbid GVHD
